|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van Klaveren RJ: Lung cancer screening.
Eur J Cancer. 47 (Suppl 3):S147–S155. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bouyssou JM, Manier S, Huynh D, Issa S,
Roccaro AM and Ghobrial IM: Regulation of microRNAs in cancer
metastasis. Biochim Biophys Acta. 1845:255–265. 2014.PubMed/NCBI
|
|
6
|
Zagryazhskaya A and Zhivotovsky B: miRNAs
in lung cancer: A link to aging. Ageing Res Rev. 17:54–67. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wan L, Zhang L, Fan K and Wang J: miR-27b
targets LIMK1 to inhibit growth and invasion of NSCLC cells. Mol
Cell Biochem. 390:85–91. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhan M, Qu Q, Wang G and Zhou H: Let-7c
sensitizes acquired cisplatin-resistant A549 cells by targeting
ABCC2 and Bcl-XL. Pharmazie. 68:955–961. 2013.PubMed/NCBI
|
|
9
|
Zhang N, Wei X and Xu L: miR-150 promotes
the proliferation of lung cancer cells by targeting P53. FEBS Lett.
587:2346–2351. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu Y, Huang J, Xu H and Gong Z:
Over-expression of miR-15a-3p enhances the radiosensitivity of
cervical cancer by targeting tumor protein D52. Biomed
Pharmacother. 105:1325–1334. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jin J, Zhang J, Xue Y, Luo L, Wang S and
Tian H: miRNA-15a regulates the proliferation and apoptosis of
papillary thyroid carcinoma via regulating AKT pathway. OncoTargets
Ther. 12:6217–6226. 2019. View Article : Google Scholar
|
|
12
|
Molina-Pinelo S, Gutiérrez G, Pastor MD,
Hergueta M, Moreno-Bueno G, García-Carbonero R, Nogal A, Suárez R,
Salinas A, Pozo-Rodríguez F, et al: MicroRNA-dependent regulation
of transcription in non-small cell lung cancer. PLoS One.
9:e905242014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
O'Connell RM, Rao DS, Chaudhuri AA and
Baltimore D: Physiological and pathological roles for microRNAs in
the immune system. Nat Rev Immunol. 10:111–122. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Codony C, Crespo M, Abrisqueta P,
Montserrat E and Bosch F: Gene expression profiling in chronic
lymphocytic leukaemia. Best Pract Res Clin Haematol. 22:211–222.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pekarsky Y and Croce CM: Role of miR-15/16
in CLL. Cell Death Differ. 22:6–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Aqeilan RI, Calin GA and Croce CM: miR-15a
and miR-16-1 in cancer: Discovery, function and future
perspectives. Cell Death Differ. 17:215–220. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Musumeci M, Coppola V, Addario A, Patrizii
M, Maugeri-Saccà M, Memeo L, Colarossi C, Francescangeli F, Biffoni
M, Collura D, et al: Control of tumor and microenvironment
cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene.
30:4231–4242. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jin W, Chen F, Wang K, Song Y, Fei X and
Wu B: miR-15a/miR-16 cluster inhibits invasion of prostate cancer
cells by suppressing TGF-β signaling pathway. Biomed Pharmacother.
104:637–644. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bonci D, Coppola V, Musumeci M, Addario A,
Giuffrida R, Memeo L, D'Urso L, Pagliuca A, Biffoni M, Labbaye C,
et al: The miR-15a-miR-16-1 cluster controls prostate cancer by
targeting multiple oncogenic activities. Nat Med. 14:1271–1277.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Janaki Ramaiah M, Lavanya A, Honarpisheh
M, Zarea M, Bhadra U and Bhadra MP: miR-15/16 complex targets p70S6
kinase 1 and controls cell proliferation in MDA-MB-231 breast
cancer cells. Gene. 552:255–264. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pouliot LM, Chen YC, Bai J, Guha R, Martin
SE, Gottesman MM and Hall MD: Cisplatin sensitivity mediated by
WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer
Res. 72:5945–5955. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bozok Çetintaş V, Tetik Vardarlı A, Düzgün
Z, Tezcanlı Kaymaz B, Açıkgöz E, Aktuğ H, Kosova Can B, Gündüz C
and Eroğlu Z: miR-15a enhances the anticancer effects of cisplatin
in the resistant non-small cell lung cancer cells. Tumour Biol.
37:1739–1751. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Çalışkan M, Güler H and Bozok Çetintaş V:
Current updates on microRNAs as regulators of chemoresistance.
Biomed Pharmacother. 95:1000–1012. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Renjie W and Haiqian L: miR-132, miR-15a
and miR-16 synergistically inhibit pituitary tumor cell
proliferation, invasion and migration by targeting Sox5. Cancer
Lett. 356B:568–578. 2015. View Article : Google Scholar
|
|
25
|
Shi L, Jackstadt R, Siemens H, Li H,
Kirchner T and Hermeking H: p53-induced miR-15a/16-1 and AP4 form a
double-negative feedback loop to regulate epithelial-mesenchymal
transition and metastasis in colorectal cancer. Cancer Res.
74:532–542. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gao W, Wang Y, Wang W and Shi L: The first
multiplication atom-bond connectivity index of molecular structures
in drugs. Saudi Pharm J. 25:548–555. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
He J: Knocking down miR-15a expression
promotes the occurrence and development and induces the EMT of
NSCLC cells in vitro. Saudi J Biol Sci. 24:1859–1865. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li H, Xu D, Toh BH and Liu JP: TGF-beta
and cancer: Is Smad3 a repressor of hTERT gene? Cell Res.
16:169–173. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xu W, Zeng F, Li S, Li G, Lai X, Wang QJ
and Deng F: Crosstalk of protein kinase C ε with Smad2/3 promotes
tumor cell proliferation in prostate cancer cells by enhancing
aerobic glycolysis. Cell Mol Life Sci. 75:4583–4598. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Paul D, Dixit A, Srivastava A, Tripathi M,
Prakash D, Sarkar C, Ramanujam B, Banerjee J and Chandra PS:
Altered transforming growth factor beta/SMAD3 signalling in
patients with hippocampal sclerosis. Epilepsy Res. 146:144–150.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ooshima A, Park J and Kim SJ:
Phosphorylation status at Smad3 linker region modulates
transforming growth factor-β-induced epithelial-mesenchymal
transition and cancer progression. Cancer Sci. 110:481–488. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang Y, Xiang J, Wang J and Ji Y:
Downregulation of TGF-β1 suppressed proliferation and increased
chemosensitivity of ovarian cancer cells by promoting BRCA1/Smad3
signaling. Biol Res. 51:582018. View Article : Google Scholar : PubMed/NCBI
|
